Role of DPP-4 inhibitors in the management of type 2 diabetes

Simple item page
dc.contributor.authorRameshen_US
dc.contributor.authorGupta, D. D.en_US
dc.date.accessioned2020-04-23T07:53:01Z
dc.date.available2020-04-23T07:53:01Z
dc.date.issued2018-12
dc.description.abstractAmong various insulinotropic agents used in treatment of Type 2 DM, inclusion of DPP4 inhibitors are considered as major breakthrough as far as new drug development is concerned. In this review article we have discussed in detail about the pathogenesis of diabetes mellitus especially the role of incretin, DPP4 enzyme and implication of its inhibitors in treatment of DM. Also, various clinical studies regarding use of DPP4 inhibitors as monotherapy and as combination therapy with other antidiabetic agents were discussed. DPP-4 inhibitors control glucose in fasting as well as in postprandial state both in monotherapy and in combination with other oral antidiabetic agents. Significant reduction in HbA1c observed with DPP4 inhibitors as monotherapy. On combining DPP 4 inhibitor as add-on therapy to metformin, glitazone or sulphonylurea therapy in patients with type 2 diabetes not reaching therapeutic goals, DPP-4 inhibitors reduce HbA1c, fasting plasma glucose and 2-h postprandial plasma glucose up to the desired level. Various DPP-4 inhibitors have been proven to be as safe and tolerable both as monotherapy and combination with other antidiabetic agents. Inhibition of DPP-4 enzyme has been proven as a promising aspect in the treatment of type 2 diabetes and various drugs inhibiting DPP4 enzymes have been developed now. They are highly recommended in the treatment of Type 2 DM both as monotherapy as well as combination therapy.en_US
dc.identifier.affiliationsDepartment of Pharmacology, Indira Gandhi Medical College Shimla, Himachal Pradesh, Indiaen_US
dc.identifier.citationRamesh, Gupta D. D.. Role of DPP-4 inhibitors in the management of type 2 diabetes. International Journal of Basic & Clinical Pharmacology. 2018 Dec; 7(12): 2488-2495en_US
dc.identifier.issn2319-2003
dc.identifier.issn2279-0780
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/199964
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber12en_US
dc.relation.volume7en_US
dc.source.urihttps://dx.doi.org/10.18203/2319-2003.ijbcp20184872en_US
dc.subjectDiabetes mellitusen_US
dc.subjectDPP4 inhibitorsen_US
dc.subjectIncretinen_US
dc.titleRole of DPP-4 inhibitors in the management of type 2 diabetesen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijbcp2018v7n12p2488.pdf
Size:
337.22 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Basic & Clinical Pharmacology